Cometriq Thyroid Approval May Open Door For Use In Prostate Cancer
As cabozantinib wins FDA approval for the rare medullary thyroid cancer, Exelixis stresses its broader development program in other tumor types, notably prostate cancer. The company is likely to submit prostate cancer data to compendia, which if successful could enable reimbursement for the off-label use.
You may also be interested in...
ASCO Round-Up: Array, Kite, Exelixis, Pfizer/Merck KGAA, Mylan, Novartis
The annual American Society of Clinical Oncology (ASCO) conference has been ongoing the last several days in Chicago, giving companies the chance to showcase their work in a range of cancers. Here's a look at some of the highlights.
Exelixis’ Cabozantinib Cleared For Kidney Cancer, With Competitive Labeling
Company plans to launch within two weeks, priced at a premium to competing drugs in kidney cancer.
Bristol, Exelixis Trials Preview Changes In Kidney Cancer Market
Commenting on pivotal trial success for Bristol’s checkpoint immunotherapy Opdivo and targeted Cometriq in renal cancer, Exelixis CEO Michael Morrissey says there’s room for two new different drugs for kidney cancer, and points out that an early stage study combining them is under way.